Patrys Limited (PAB.AX)
ASX · AUD
A$0.025 (-3.85%) as of
Key statistics
- Market cap
- 8.76M
- EPS (TTM)
- -0.0200
- 52-week range
- 0.0250 – 0.0520
- Beta
- 1.27
- Revenue (TTM)
- 8.98k
- Profit margin
- 0.00%
- Analyst target
- A$0.13
- Volume
- 644.15k
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
- Headquarters
- Nedlands, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.